All In Biotech

Drug Trial Radar · NCT06566079

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Dec 27, 2024

Primary completion

Aug 31, 2027

Study completion Feb 28, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection expansion part (Part 2).

Conditions

  • Malignant Mesothelioma
  • Metastatic Malignant Solid Tumor
  • Advanced Solid Tumor

Interventions

  • ISM6331Drug

    Dosage form: Capsule for oral administration. Frequency of administration: Once daily overall of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT).Time frame: Day 1 up to Day 31
  2. Incidence and severity of adverse events (AEs)Time frame: Approximately 12 months.
  3. Incidence of clinically significant abnormalities in laboratory values, vital signs, physical examination, and electrocardiogram (ECG) measurements.Time frame: Approximately 12 months.
  4. Recommended Phase 2 Dose (RP2D)Time frame: Approximately 40 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • The University of Chicago Medical Center - Duchossois Center for Advanced Medicine

    Chicago, Illinois · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania - Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • NEXT Oncology - Austin

    Austin, Texas · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.